NCT05981235View on ClinicalTrials.gov

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

June 25, 2025

Study Completion Date

June 25, 2025

Conditions
Gastrointestinal Tumors
Interventions
BIOLOGICAL

AZD6422 CLDN18.2 CAR-T product

AZD6422 CAR-T product infusion after pre-conditioning

Trial Locations (1)

Unknown

peking university Cancer Hospital, Beijing

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Peking University

OTHER